Skip to main content
BLRX
NASDAQ Life Sciences

BioLineRx Registers 2.02M ADSs for Resale by Armistice Capital

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$2.37
Mkt Cap
$12.635M
52W Low
$2.15
52W High
$4.56
52W Position info
10% above low
Off High info
48% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

BLRX is trading near its 52-week low of $2.15 (10% above the low) on light trading volume (0.2× avg).

Summary

BioLineRx registered 2.02 million ADSs for resale by Armistice Capital, making the August 2026 warrant shares freely tradable and potentially generating $5.6 million in cash if exercised.


Key Events · Financing and Capital Events · BLRX

  • Resale Registration Effective

    2,023,382 ADSs underlying August 2026 private placement warrants are now registered for resale by Armistice Capital, removing trading restrictions on the overhang.

  • Selling Shareholder Identified

    Armistice Capital, LLC is the selling shareholder and would beneficially own 21.4% of ordinary shares after full warrant exercise (900,763,800 ordinary shares remaining).

  • Potential Cash Proceeds

    If all warrants are exercised for cash, BioLineRx would receive $5.6 million, which it intends to use for R&D, working capital, and general corporate purposes.

  • Going Concern Context

    The registration follows BioLineRx's August 31, 2026 disclosure of going concern uncertainty with only $13.1 million in cash, making the potential warrant proceeds material to runway.


Analysis · BLRX · Life Sciences

This prospectus makes the 2.02 million ADSs underlying the August 2026 private placement warrants freely tradable by Armistice Capital. The registration removes a key restriction on the overhang, meaning Armistice can now sell into the market at any time. If all warrants are exercised for cash, BioLineRx would receive $5.6 million — meaningful runway for a company that flagged going-concern uncertainty with only $13.1 million in cash as of August 31, 2026. The selling shareholder would hold 21.4% of ordinary shares after full exercise, making this a significant ownership event.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BLRX was trading at $2.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.6M. The 52-week trading range was $2.15 to $4.56. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BLRX - Latest Insights

BLRX
Sep 10, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.22
Real-time Price: $1.19 info
Change: -$1.03 (-47%) info
Market Cap: $9.283M info
BLRX
Aug 31, 2026, 11:19 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $2.74
Real-time Price: $1.19 info
Change: -$1.55 (-57%) info
Market Cap: $9.283M info
BLRX
Aug 31, 2026, 10:23 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.69
Real-time Price: $1.19 info
Change: -$1.50 (-56%) info
Market Cap: $9.283M info
BLRX
Aug 31, 2026, 7:15 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.73
Real-time Price: $1.19 info
Change: -$1.54 (-57%) info
Market Cap: $9.283M info
BLRX
Aug 28, 2026, 8:12 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.21
Real-time Price: $1.19 info
Change: -$1.02 (-46%) info
Market Cap: $9.283M info